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ciencyandnaturalkillercell lympho-
penia caused by Ets-binding site
mutation in the IL-2 receptor g
(IL2RG) gene promoterTo the Editor:
Patients with severe combined immunodeficiency (SCID) of
a classical phenotype present within the first year of life with
life-threatening infections and failure to thrive.1 The X-linked
T2B1 natural killer (NK)2 form of SCID is the most
frequent type (44% to 46%) and is a consequence of muta-
tions in the IL-2 receptor g (IL2RG) gene (OMIM 308380),
which encodes the common cytokine receptor g chain (gc).2
The gc acts as a signal-transducing subunit of cytokine recep-
tors that are essential in the ontogeny and function of T, B,
and NK cells, namely IL-2, IL-4, IL-7, IL-9, IL-15, and IL-
21. The intracellular part of gc interacts with Janus kinase
3 and mediates phosphorylation and activation of signal trans-
ducer and activator of transcription (STAT) proteins, which
regulate induction of gene transcription.
A number of patients with a milder form of combined immuno-
deficiency, often termed ‘‘leaky’’ or ‘‘hypomorphic’’ SCID, have
been described. Here we describe 2 male relatives with a novel
hypomorphic mutation in the IL2RG promoter who presented with
a phenotype more akin to common variable immunodeficiency
(CVID). CVID is the most common clinically and genetically
heterogeneous primary immunodeficiency, which is characterized
by low IgG, IgA, and/or IgM levels, with a failure to produce
specific antibodies.3 Mutations in genes encoding transmembrane
activator and CAML interactor (TACI), inducible costimulator
(ICOS), CD19, CD20, CD21, CD81, LRBA, CXCR4, NF-kB2,
B cell–activating factor of the TNF family (BAFF) receptor,
TNF-related weak inducer of apoptosis (TWEAK), phosphoinosi-
tide 3-kinase catalytic subunit d polypeptide (PI3KCD), and
PI3KR1 were shown to cause CVID-like phenotypes.3
The grandson presented at age 4 years with a history of
recurrent bacterial otitis media and chronic suppurative rhinitis,
rotavirus-induced gastroenteritis (age 18 months), echoviral
gastroenteritis (age 2 years), and varicella zoster (age 4 years).
He had IgG deficiency (1.8 g/L) with normal IgA and IgM levels
(1.0 and 0.5 g/L, respectively) and did not mount an adequate
response to the 23-valent pneumococcal polysaccharide vaccine 2015 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).(Pneumovax; Merck & Co, Whitehouse Station, NJ), although he
responded appropriately to immunization with protein antigens
(see Table E1 in this article’s Online Repository at www.
jacionline.org). He had normal numbers of T and B cells but
completely absent NK cells. T-cell proliferation after stimulation
with PHA, anti-CD3, andCandida species was suboptimal but not
completely abrogated. He was started on immunoglobulin
replacement therapy and is well, with his infections limited to
recalcitrant cutaneous warts.
At the time of his diagnosis, it was noted that his maternal
grandfather was under treatment for CVID. The grandfather
presented to an immunology team at the age of 34 years with a
20-year history of recurrent otosinopulmonary tract infections
with Streptococcus pneumoniae and Haemophilus influenzae,
bronchiectasis, and type 1 diabetes mellitus and celiac disease.
On initial presentation, he had an IgG2 and IgG4 subclass
deficiency, absent antibody response to polysaccharide vaccine,
CD4 and NK lymphopenia, and reduced proliferative responses
to PHA. Immunoglobulin substitution was implemented, along
with antibiotic prophylaxis, and he was managed successfully
on this regimen for 25 years until he died at age 62 years after a
cardiac event.
Flow cytometric analysis of lymphocytes revealed a signifi-
cantly diminished gc expression in both the grandson and
grandfather (Fig 1, A; see theMethods section in this article’s On-
line Repository at www.jacionline.org). Likewise, IL2RGmRNA
expression in sorted T and B cells from the grandson showed a
4.2-fold reduction in T cells and a 33-fold reduction in B cells
compared with healthy control subjects (Fig 1, B). The T cells
were then stimulated with IL-2, IL-7, and IL-15, and phosphory-
lated STAT5 levels were determined by means of flow cytometric
analysis (Fig 1, C). This was diminished in the patient with a fold
reduction compared with healthy control samples of 3.5-, 7.5-,
and 3.8-fold for IL-2, IL-7, and IL-15, respectively.
X-inactivation studies performed on samples from the
mother of the grandson demonstrated random X-inactivation
in whole blood but apparent nonrandom X-inactivation in
T cells (see Table E2 in this article’s Online Repository at
www.jacionline.org). Whole-exome sequencing of the grandson
revealed a point mutation, C to T at position g.chrX:71,111,618
(GRCh38), which was located 213 nucleotides upstream of the
transcription start site in the IL2RG gene (ENST00000374202;
Fig 1, D). This is situated at an identified binding site for the
transcription factor ETS, which is required for basal promoter
activity in cell lines.4
For functional validation, we generated the samemutation in an
IL2RG minigene (Mut.gcPRO and WT.gcPRO), and using a
lentiviral vector, introduced this into gc-deficient ED7R cells.
We found that gc expression from Mut.gcPRO was dramatically
abrogated when compared with the wild-type sequence in a
dose-dependent manner. When transduced at similar efficiency
(similar vector copy numbers), there is an 8-fold difference in
gc expression between the WT-gcPRO and Mut-gcPRO trans-
duced cells (Fig 1, E). To confirm that the mutation abrogated
binding of ETS, using the electrophoretic mobility shift assay,
we showed that mutant oligonucleotides were unable to form a
normal protein/DNA complex (Fig 2).
More than 100 mutations in IL2RG have been described
extending across all of its 8 exons, intron/exon boundaries, and
39 regulatory regions.4 Although most of the known mutations
result in a classical immunophenotype of T2B1NK2 SCID,
FIG 1. Reduced IL2RG expression and function. A and B, Common gc expression on lymphocytes (Fig 1, A)
in a control subject (CON), the grandson (GS), and the grandfather (GF), as well as IL2RGmRNA expression
(Fig 1, B). C, Phosphorylated STAT5 (pSTAT5) expression after stimulation with cytokines (dark gray) or
unstimulated (light gray). Mean fluorescence intensities are shown in parentheses. D, Illustration of the
point mutation in the IL2RG promoter with the ETS consensus sequence underscored. E, Expression of
common gc after transduction of ED7R cells. The vector copy number (VCN) per cell is shown.
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been described.5,6 Attenuated SCID phenotypes have also been
observed as a result of splice-site mutations resulting in
diminished expression of truncated gc protein or as a result of
somatic reversion.5-7
Here we identified a novel point mutation at nucleotide 213
upstream of the transcription start site in a putative ETS-binding
site.3 ETS transcription factors comprise a large evolutionarily
conserved family characterized by sequence homology within
their DNA-binding domain that bind to sequences containing a
consensus GGAA/T motif.8 The ETS transcription factors have
been linked with diverse biological processes, including hemato-
poiesis, T-cell survival, and NK cell production.9 Previous studies
have shown that an ETS-binding site in a 1053-bp fragment 59 tothe IL2RG transcription initiation site is essential for tissue-
specific basal promoter activity of IL2RG.3
Our data indicate that a point mutation within the ETS-binding
site of the proximal IL2RG promoter has a significant detrimental
effect on its activity in human subjects. The residual expression of
gc appears to differentially affect signaling through the cytokine
receptors leading to normal T-cell development, with minimal
reduction in T-cell function and absent NK cell development. In
this family this resulted in an initial presentation akin to CVID,
manifesting with recurrent bacterial and viral infections. This
scenario should be considered in male patients with antibody
deficiency, particularly if accompanied by NK lymphopenia.
These patients should also be monitored closely for more serious
manifestations because this defect is amenable to correction by
FIG 2. Electrophoretic mobility shift assay. Biotin-labeled wild-type or
mutant oligonucleotides incubated without nuclear extracts (lanes 1 and
4), with nuclear extracts (lanes 2, 3, 5, and 6), and in the absence (lanes 2
and 5) or presence (lanes 3 and 6) of an excess of unlabeled oligonucleo-
tides. A supershift DNA/protein complex band is detected and marked.
The free-labeled oligonucleotide is indicated.
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Furthermore, our finding highlights the potential role ofmutations
in gene regulatory regions as a cause of significant primary
immunodeficiencies.
We thank Niek P. van Til, Department of Hematology, Erasmus University
Medical Center, Rotterdam, The Netherlands, for providing the wild-type
gcPRO plasmid.
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ness and impaired development in
a CD247-deficient patientTo the Editor:
The analysis of single gene defects in patients with primary
immunodeficiencyhas provided important insights into the normal
physiology of the immune system and is particularly valuable in
those instances where the human and murine immune systems are
different.1 CD247 (T-cell receptor [TCR] z/CD3z) is one of the
invariant chains that, alongwith CD3g, CD3d, CD3ε, and a clono-
typic TCR heterodimer (ab or gd), forms the TCR antigen recep-
tor complex expressed at the surfaces of T lymphocytes. However,
CD247 is also expressed in natural killer (NK) cells, and although
the biology of CD247 in the TCR complex is similar in mice and
human subjects, there are marked differences between human
and murine NK cells in the expression and association of acti-
vating NK receptors (CD16/FcgRIII, natural cytotoxicity receptor
(NCR)3/NKp30, and NCR1/NKp46) with CD247.2,3 Thus anal-
ysis of the rare patients deficient in CD247 provides unique in-
sights into the biology of this signaling molecule in NK cells
that cannot be obtained from the study of murine models.
Two CD247-deficient patients have been described previ-
ously.4,5 Those studies focused on the effects of this deficiency
on T cells, and although a somewhat reduced NK cell activity
was noted, this population was not studied in detail. Here we
report in-depth analyses of NK cells in a new case of inherited
METHODS
Patients and ethics
All material from patients was obtained with informed consent from adults
and from the parents of children who participated in the study in accordance
with the Declaration of Helsinki and with approvals from the ethics
committees of Cambridge University Hospitals NHS Foundation Trust and
Royal Free Hospital and Medical School (REC 04/Q0501/119).
Determination of IL2RG mRNA expression in
peripheral blood by using quantitative RT-PCR
Cell separation from peripheral blood cells. A subset of T and B
cells from control and patient samples were obtained by incubating PBMCs
with anti-CD3 and anti-CD19 antibodies conjugated with magnetic
microbeads (Miltenyi Biotec, Surrey, United Kingdom). Then the cells were
separated with the autoMACS Pro Separator (Miltenyi Biotec).
Total RNA isolation and reverse transcription. Total RNA was
extracted from sorted T and B cells by using the RNeasy kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions. The cDNA was
synthesized with the QuantiTect Reverse Transcription Kit (Qiagen). First,
RNA (100 ng) was incubated with genomic DNAWipeout Buffer at 428C for
5 minutes. Then Reverse Transcription master mix containing RT primer and
Quantiscript Reverse Transcriptase (Qiagen) was added to the RNA. The
reaction was then incubated for 15 minutes at 428C, followed by 3 minutes at
958C to inactive reverse transcriptase.
Real-time quantitative PCR. Quantitative PCRwas performed with an
ABI 7000 Sequence Detection System (Applied Biosystems, Warrington,
United Kingdom). The primer sequences for IL2RGwere as follows: forward,
5-TGCTAAAACTGCAGAATCTGGT -3; reverse, 5-AGCTGGGATTCACT
CAGTTTG-3. The IL2RG probe sequence was 5-CCTGGGCTCCAGAGA
ACCTAACA-TAMRA-3. The primer sequences for the human b-actin gene
were as follows: forward, 5-TCACCCACACTGTGCCCATCTACGA-3;
reverse, 5-CAGCGGAACCGCTCATTGCCAATGG-3. The b-actin probe
sequence was 5-FAM-ATGCCCTCCCCCATGCCA TCCTGCGT-TAMRA-3.
The average cycle threshold (Ct) values for IL2RG from quantitative PCR
were normalized with the average Ct value of b-actin to give rise to the
DCt, which is used to calculate the DDCt value. Then the 22DDCt values for
healthy control subjects and patients were deduced from the DDCt value.
Quantitative PCR was run in duplicates in 3 independent experiments. Two
different controls were used.
Generation of the mutant IL2RG construct
The mutant IL2RG promoter was generated by using the QuikChange
Lightning Site-DirectedMutagenesis Kit (Agilent Technologies,Wokingham,
Berkshire, United Kingdom). The lentiviral vector containing the wild-type
IL2RG promoter driving codon optimized IL2RG (lenti-gcPRO.gc.co)E1 was
used as the parental sequence. The primer sequences used in PCR were as
follows: forward, 5-ggttctttccactggaagctatgacag-3; reverse, 5-ctgtcatagctt
ccagtggaaagaacc-3. The PCR reaction was performed according to the manu-
facturer’s instructions. PCR product was then incubated with DpnI enzyme at
378C for 5 minutes to digest parental plasmid DNA. Digested PCR product of
2mLwas transformed into XL10-Gold cells provided within the kit, according
to the protocol. The plasmids prepared from single colonies were then
sequenced to confirm introduction of the point mutation within the IL2RG
promoter and to obtain the lenti-mut.gcPRO.gc.co construct.
Lentivirus preparation
Lentivirus was produced by means of transient cotransfection of
HEK293T cells with 3 plasmids, the lentiviral vectors for lenti-gcPRO.gc.co
and lenti-mut.gcPRO.gc.co, pMD.G2 (envelope plasmid), and pCMV_8.91
(packaging plasmid, both produced by Plasmid Factory, Bielefeld, Germany),
by using polyethylenimine (Sigma-Aldrich, St Louis, Mo), as previously
described.E2
Determination of viral titer. Mouse fibroblast SC-1 cells were
transduced with serial dilutions of virus. Genomic DNA was isolated from
transduced cells by using the DNeasy Kit (Qiagen). Viral vector copy number
was determined by using quantitative PCR. The primers for the lentiviral
vector were as follows: forward, 5-CAGGACTCGGCTTGCTGAAG-3;
reverse, 5-TCCCCCGCT TAATACTGACG-3. The probe for lentiviral vector
was 5-FAM-CGCACGGCA AGA GGC GAG G TAMRA-3. The primer
sequences for the mouse housekeeping titin gene (Ttn) were as follows: for-
ward, 5-AAAACGAGCAGTGACCTGAGG-3; reverse, 5-TTCAG TCATGC
TGCTAGCGC-3. The Ttn probe sequence was 5-FAM-TGCACGGAATCTC
GTCTC AGTC-TAMRA-3.
IL2RG expression analyzed by using fluorescence-
activated cell sorting
IL2RG expression in vitro after lentivirus transduction. ED7R
cells derived from an adult human T-cell leukemia line deficient in IL2RG
gene expression were cultured in RPMI 1640 plus 10% FCS. The cells
were seeded into 12-well plates (105 cells/well) and transduced with the
lenti-gcPRO.gc.co or lenti-MutgcPRO.gc.co viruses at different multiplic-
ities of infection. On day 3 after transduction, half of the transduced cells
were resuspended in 100 mL of fluorescence-activated cell sorting (FACS)
buffer (0.5% BSA/PBS) containing 0.5 mL of anti–human IL2RG (BD Bio-
sciences, San Jose, Calif) and incubated for 30 minutes at 48C. The cells
were then washed with FACS buffer, and IL2RG expression was analyzed
by using FACS. Half of the transduced cells were pelleted for extraction of
genomic DNA, and the vector copy numbers were determined by using
quantitative PCR, as described above. The housekeeping gene albumin
was used as the internal reference gene. The primers/probes used for the
lentivirus vector is the same as the above. The primers for the human albu-
min gene were as follows: forward, 5-GCT GCT ATC TCT TGT GGG
CTG T; reverse, 5-ACT CAT GGG AGC TGC TGG TTC. The albumin
probe was 59-VIC-CCT GTC ATG CCC ACA CAA ATC TCT CC-
TAMRA-3.
IL2RG expression in patients. Three microliters of anti-human
IL2RG (BD Biosciences) or matched isotype control (BD Biosciences)
was added to 100 mL of blood incubated for 10 minutes at room tempera-
ture. Red blood cells were lysed with FACsLyse (BD Biosciences) for 10 mi-
nutes and then washed with Cell Wash (BD Biosciences) before being fixed
(FACsFix, BD Bioscience). Ten thousand lymphocytes were acquired
(FACSCalibur, BD Biosciences) and analyzed (CellQuest Pro, BD
Biosciences).
FACS analysis of STAT5 tyrosine phosphorylation in T cells.
IL-2 (13 104 IU/mL; Chiron, Austin, Tex), IL-7 (100 ng/mL; R&D Systems,
Minneapolis,Minn), or IL-15 (50 ng/mL, R&DSystems) was added to 100mL
of whole blood and placed at 378C for 10 minutes to stimulate cells. Two
milliliters of prewarmed FACsLyse/Fix (BD Biosciences) was then added to
the blood, mixed, and placed at 378C for 10 minutes. The cells were pelleted
and washed once with STATwash (PBS containing 1% FCS). The cells were
resuspended in cold Perm Buffer III (BD Biosciences) and placed at 48C for
30 minutes. The cells were then washed once with STAT wash before 5 mL
of antibody (STAT5 ptyr and CD4 peridinin-chlorophyll-protein complex
[PerCP]; BD Biosciences) was added, and the cells were incubated at room
temperature for 30 minutes in the dark, washed with STAT wash, and fixed
(FACsFix, BD Biosciences). Ten thousand lymphocyte events were acquired
(FACsCalibur, BD Biosciences) and analyzed with CellQuest software (BD
Biosciences).
Electrophoretic mobility shift assay
Nuclear proteins were extracted from Jurkat and ED7R cells by using the
NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Scientific,
Waltham, Mass), according to the manufacturer’s instructions. The extracted
nuclear proteins were then placed in aliquots and stored at 2808C. A 38-bp
oligonucleotide was chosen from the IL2RG promoter covering the
Ets-binding region with the following sequences: wild-type, 59 ATA AGG
TTC TTT CCA CCG GAA GCT ATG ACA GAG GAA AC; mutant,
59 ATA AGG TTC TTT CCA CTG GAA GCT ATG ACA GAG GAA AC.
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The oligonucleotides were synthesized and HPLC purified by Invitrogen
(Carlsbad, Calif). Biotin labeling of the oligonucleotides was performed by
using the Biotin 39 End DNA Labeling Kit (Thermo Scientific), according
to the manufacturer’s instructions. The labeled oligonucleotides were purified
with chloroform:isoamyl alcohol. An equal molar-labeled sense and antisense
oligonucleotide was annealed in 10 mmol/L Tris, 1 mmol/L EDTA, and
50 mmol/L NaCl at 958C for 5 minutes and then 218C/cycle down to 598C,
followed for 30 minutes at 598C, and then 218C/cycle down to 208C in the
thermocycler. The same annealing process was also applied to the unlabeled
oligonucleotides.
The binding assay was performed with the LightShift Chemiluminescent
ElectrophoreticMobility Shift AssayKit (Thermo Scientific), according to the
manufacturer’s instructions. The binding reaction contained 1 3 binding
buffer, 2.5% glycerol, 5 mmol/LMgCl2, 50 ng/mL Poly(dI*Dc) 0.05%NP-40,
4 pmol of unlabeled oligos (200 3 excess), and 20 fmol of biotin-labeled
oligonucleotides in a total volume of 20 mL. The reaction was incubated at
room temperature for 20 minutes and then loaded onto a 6% DNA retardation
TBE gel (Invitrogen). After electrophoresis, the gel was transferred to the
nylon membrane (Invitrogen). The membrane was then UV cross-linked for
12 minutes and incubated in blocking buffer for 15 minutes, followed by
incubation with streptavidin–horseradish peroxidase in blocking buffer. The
membrane was then washed with 1 3 wash buffer, followed by Substrate
Equilibration Buffer (Thermo Scientific). Finally, the membrane was incu-
bated with Substrate Working buffer for 5 minutes before exposure with the
CCD camera.
X-inactivation studies
X-inactivation studieswere performed by theNorth East Regional Genetics
Laboratory on DNA from whole blood and magnetically separated T cells
(anti-CD3 beads and autoMACs, Miltenyi Biotec), as previously described.E3
This analyzes methylation at the androgen receptor locus. Briefly, extracted
DNA was incubated with or without the restriction enzyme HpaII,
amplified, and analyzed on a sequencing gel. In female subjects with random
X-inactivation, 2 bands are detected, and only 1 band is detected in those with
nonrandom X-inactivation.
Patients’ immunologic data. Immunophenotyping of lymphocyte
populations was performed by using flow cytometry.Whole bloodwas labeled
with combinations of mAbs conjugated with fluorescein isothiocyanate
(FITC), phycoerythrin (PE), allophycocyanin (APC), PerCP, or fluorochrome
combinations with cyanines (PerCP-Cy5.5, APC-Cy7, and PE-Cy7; BD
Biosciences). Lymphocyte subsets were detected by using a 6-color multitest
reagent containing CD3 FITC, CD161CD56 PE, CD45 PerCP-Cy5.5, CD19
APC, CD4 PE-Cy7, and CD8-APC-Cy7. Naive, effector, and memory T-cell
populations were detected with CD45RA FITC, CD27 PE, CD45 PerCP, and
CD4 or CD8 APC. Naive, memory, and switched B-cell populations were
detected by using CD19 PE-Cy7, CD27 PE, IgD FITC, and IgMCy5. Staining
was analyzed on a FACSCanto II flow cytometer (BD Biosciences).
Immunoglobulin levels were measured with a Dade Behring (Milton
Keynes, United Kingdom) nephelometer (BNII), according to the manufac-
turer’s instructions.
Proliferation assays. PBMCs (5 3 105) were seeded onto a 96-well
plate in RPMI containing 5% human AB serum. Mitogens (CD3 and PHA)
or antigen (Candida species) were added to the wells in a final volume of
200 mL. A minimum of 3 replicates were performed on each sample, with a
healthy control subject. Four days later, plates treated with mitogens were
pulsed with 1 mCi/mL tritiated thymidine for 4 hours. Antigen plates were
pulsed after 6 days, cells were harvested, and thymidine incorporation was
measured on a scintillation counter.
Whole-exome sequencing
Library preparation, exome capture, and sequencing have been done
according to themanufacturers’ instructions. For exome target enrichment, the
Agilent SureSelect 50 Mb kit (Agilent, Santa Clara, Calif) was used.
Sequencing was done with the Illumina HiSeq with 94-bp paired-end reads.
Reads from raw FASTQ files were aligned to the hg19 reference genome by
using NovoAlign, version 2.08.03 (Novocraft Technologies, Selangor,
Malaysia). Duplicate reads were marked with picard tools mark duplicates.
Calling was performed with the haplotype caller module of GATK (https://
www.broadinstitute.org/gatk), creating gVCF formatted files for each sample.
The individual gVCF files were combined into gVCF files containing 100
samples each. The final variant calling was performed with the GATK
‘‘GenotypegVCFs’’ module used jointly for all patients and control subjects.
Variant quality scores were then recalibrated according to GATK best
practices separately for indels and single nucleotide polymorphisms.
Resulting variants were annotated with ANNOVAR.
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TABLE E1. Summary of immunologic investigations in the patients
Investigation Grandson 44 y (normal range) Grandson 4 y (normal range)
CD31 cells (109/L) 0.83 (0.7-2.1) 4.34 (0.9-4.5)
CD191 cells (109/L) 0.01 (0.1-0.5) 1.10 (0.2-2.1)
CD161CD561 cells (109/L) 0.00 (0.09-0.6) 0.00 (0.1-1.0)
CD31CD41 cells (109/L) 0.25 (0.3-1.4) 2.86 (0.5-2.4)
CD31CD81 cells (109/L) 0.53 (0.2-0.9) 1.21 (0.3-1.6)
gd T cells (109/L) 0.03 1.39
Naive CD41 T cells (CD271CD45RA1) 50% (>50%)
Naive CD81 T cells (CD271CD45RA1) 61% (>50%)
PHA, 0 mg/mL (mean CPM) 68 57
PHA, 4 mg/ml (mean CPM) 3,859 (>12,000) 10,909 (>12,000)
CD3 background (mean CPM) 167 183
CD3 stimulated (mean CPM) 484 (>7,500) 3,952 (>7,500)
Candida species background (mean CPM) 630 904
Candida species stimulated (mean CPM) 5,274 (>12,500) 9,252 (>12,500)
IgG (g/L) 7.2 (6-13) 1.8 (4.9-16.1)
IgG1 (g/L) 4.66 (3.1-8.9)
IgG2 (g/L) 0.58 (1.4-5.5)
IgG3 (g/L) 0.26 (0.04-1.07)
IgG4 (g/L) 0.00 (0.01- 0.93)
IgA (g/L) 2.3 (0.8-3.7) 1.0 (0.4-2.0)
IgM (g/L) 2.4 (0.4-2.2) 0.5 (0.5-2.0)
CD41 TRECs per million T cells 19,057 (>20,000)
CD81 TRECs per million T cells 34,125 (>20,000)
Naive B cells (IgD1IgM1CD272) 98% (70% to 90%)
Anti-tetanus antibody (IU/mL) <10 IU (undetectable) 0.28 (protective range)
Anti-pneumococcal antibody <10 IU (undetectable);
no response on immunization
220 before immunization/352 after immunization (640 units
of range for unimmunized subject)
Anti-rubella antibody 4 (>10)
Anti–varicella zoster antibody 43 (>20)
Anti-mumps antibody IgG positive
Anti-measles antibody 1.4 (detectable)
Anti-HiB antibody (mg/mL) 2.17 before immunization/>14 after immunization (optimal >1)
CPM, Counts per minute; TRECs, T-cell receptor excision circles.
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